The goal of this observational study is to evaluaty the accuracy of current risk stratification of patients with endometrial cancer and to redefine lymph node staging recommendations based on real-world clinical data. The main question it aims to answer is:

Is there any group of patients who doesn't need lymph node staging for proper indication of adjuvant treatment? Participants are note taking any intervention. They are treated according to current standard of care and followed 3-years after primary surgery.

Inclusion Criteria:

• Women ≥18 years with newly diagnosed endometrial cancer (any histology)
• Undergoing primary surgical management
• Preoperative expert ultrasound, CT scan (could be waived in low risk cases)
• Preoperatively early-stage (stage I-II) of EC
• SLN mapping attempted intraoperatively
• FFPE tumor tissue available for molecular and IHC testing from biopsy
• Signed informed consent with the participation in the study

Exclusion Criteria:

• Neoadjuvant treatment
• Recurrent or metastatic disease at diagnosis
• Inadequate imaging or tissue samples
• Cancer synchronous duplicity
• Prior oncological treatment within the last five years

Patients with histologicaly confirmed endometrial cancer.